Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Sarcoidosis

ClinicalTrials.gov lists 279 trials for Sarcoidosis or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 8.

MeSH D012507 Hemic and Lymphatic Diseases C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 7 Phase 1/2 Phase 1/2 7 Phase 2 Phase 2 35 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 13 Phase 4 Phase 4 21 Not applicable Not applicable 69 Observational Observational 116 Phase 1 Phase 1 7 Phase 1/2 Phase 1/2 7 Phase 2 Phase 2 35 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 13 Phase 4 Phase 4 21 Not applicable Not applicable 69 Observational Observational 116

Trials per phase

247 of the 279 trials are tagged with Sarcoidosis itself; the rest are tagged with a narrower condition beneath it.

Get the Sarcoidosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Sarcoidosis trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 24

1991: 1 trials (Observational 1) 1995: 1 trials (Observational 1) 1996: 2 trials (Observational 2) 1998: 1 trials (Observational 1) 1999: 2 trials (Observational 1, Phase 2 1) 2000: 1 trials (Observational 1) 2002: 1 trials (Observational 1) 2003: 3 trials (Phase 3 2, Phase 1/2 1) 2004: 5 trials (Observational 3, Not applicable 1, Phase 4 1) 2005: 5 trials (Observational 4, Phase 3 1) 2006: 11 trials (Observational 4, Not applicable 2, Phase 4 2, Phase 2 3) 2007: 4 trials (Observational 2, Not applicable 1, Phase 2/3 1) 2008: 11 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 2/3 3, Phase 2 2, Phase 1 1) 2009: 12 trials (Observational 3, Not applicable 3, Phase 3 2, Phase 2 4) 2010: 6 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 1/2 1, Phase 1 1) 2011: 8 trials (Observational 5, Not applicable 2, Phase 1 1) 2012: 9 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 1) 2013: 11 trials (Observational 2, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2 1) 2014: 15 trials (Observational 4, Not applicable 4, Phase 4 2, Phase 2/3 1, Phase 2 4) 2015: 15 trials (Observational 5, Not applicable 5, Phase 4 2, Phase 2/3 2, Phase 1/2 1) 2016: 14 trials (Observational 4, Not applicable 7, Phase 2/3 2, Phase 2 1) 2017: 13 trials (Observational 7, Not applicable 3, Phase 4 2, Phase 1 1) 2018: 13 trials (Observational 6, Not applicable 5, Phase 4 1, Phase 1 1) 2019: 24 trials (Observational 11, Not applicable 5, Phase 4 1, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2020: 9 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 2 2) 2021: 15 trials (Observational 11, Not applicable 1, Phase 2 2, Phase 1 1) 2022: 18 trials (Observational 6, Not applicable 6, Phase 4 1, Phase 3 2, Phase 2 3) 2023: 10 trials (Observational 3, Not applicable 3, Phase 3 2, Phase 2 1, Phase 1/2 1) 2024: 16 trials (Observational 7, Not applicable 3, Phase 4 3, Phase 2 2, Phase 1/2 1) 2025: 8 trials (Observational 4, Not applicable 1, Phase 2/3 1, Phase 2 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 12
2025 8
2024 16
2023 10
2022 18
2021 15
2020 9
2019 24
2018 13
2017 13

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 12 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 12 already registered with a 2026 start date: at the cutoff, 3 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

Prediction, not a registry value: median of 34 months from start to primary completion across 16 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 149 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Sarcoidosis trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 7
Phase 1/2 7
Phase 2 35
Phase 2/3 11
Phase 3 13
Phase 4 21
Not applicable 69
Observational 116

How many Sarcoidosis trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 10
Recruiting 35
Enrolling by invitation 3
Active, not recruiting 9
Completed 138

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Sarcoidosis trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 8
National Eye Institute (NEI) 4
Novartis Pharmaceuticals 3

Which drugs are being tested for Sarcoidosis? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Prednisone 6
THALIDOMIDE 2
Nicotine Patch 2
INFLIXIMAB 2
Namilumab 2

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Acthar low dose (40 U) 5
Adalimumab-US 4
BLOOD SAMPLE 3
Bronchoalveolar lavage 3
Observational Study 2

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Sarcoidosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 19 6
Acute respiratory failure 5 3
Atrial fibrillation 5 3
Hypoxia 5 2
Influenza 5 4

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Sarcoidosis? (194)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China. The Journal of rheumatology 2025 Yes
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis. Rheumatology (Oxford, England) 2024 Yes
Needle-based confocal laser endomicroscopy for real-time granuloma detection. Respirology (Carlton, Vic.) 2023 Yes
Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023 Yes
Risk Indicators of Sarcoidosis Evolution-Unified Protocol (RISE-UP): protocol for a multi-centre, longitudinal, observational study to identify clinical features that are predictive of sarcoidosis progression. BMJ open 2023 Yes

Showing 5 of 194 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (102)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Sarcoidosis Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Sarcoidosis Annual incidence 1-9 / 100 000 United Kingdom GB Unspecified
Sarcoidosis Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Sarcoidosis Point prevalence 6-9 / 10 000 United States US Unspecified
Sarcoidosis Point prevalence 6-9 / 10 000 United States US Exact

Showing 5 of 102 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Sarcoidosis 797 Exact Orphanet Rare Disease Ontology (ORDO)
Sarcoidosis 797 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages